Bristol-Myers Squibb dismissed it as “rumors and speculation.” Elan declines to comment. And UBS says BMS has it has “confirmed” that it isn’t happening. Yet Elan’s stock continues to float on the idea that BMS is about to buy some or all of the company. As the graphic shows (click to enlarge), Elan’s stock rose from around 6.70 to more than 7.50 over...
Pharma Industry Archive
June 2009
Pharma and biotech companies are less interested in cures and more interested in medications that require a lifetime of administration, according to scientists at last week’s annual meeting of the American Society of Gene Therapy. The poor folks in gene therapy haven’t had it easy. Their approach has yet to gain FDA approval, so there’s no regulatory precedent. Toxicity issues...
Attorneys in Ohio are gathering plaintiffs to sue Bayer over its Yaz birth control pill, claiming it causes potentially fatal blood clots. The suits come after Bayer reached an agreement with the FDA to run $20 million in corrective advertising after the company’s TV spots misleadingly claimed the pill could cure acne and PMS. Although such suits are predictable — virtually all...
Sanofi-Aventis may take the heavier hit in its partnership with Bristol-Myers Squibb as the anticoagulant Plavix goes generic in Europe. The Eurozone gave a green light to six Plavix generics last week. Sanofi and BMS co-market the product in both the U.S. and Europe. Although BMS is frequently mentioned in regard to its looming generic cliff, A look at their Q1 2009 earnings statements shows...
- Novartis Looks at Combination Pills to Fix Hypertension Franchise
- Study Showing Drug Ads Are Linked to Higher Prices Has Flaws
- Bankers Reveal Top Biotech IPO Contenders; New Filer Ironwood Among Them
- Pfizer Got $160M in Tax Money to Build in Connecticut
- Sanofi's Viehbacher Backs Health Reform; May Change Company's Name
- Viagra Now Available Intravenously
- Genzyme Kidney Drug Failed, Too...What Could Possibly Happen Next?
- Peter Pitts' CMPI Targeted Over Anti-Healthcare Reform Video Game
- Why Allergan and Medicis Should Embrace the "Botox Tax" in Senate Health Bill
- Why J&J's Stelara Launch Should Target Dermatologists First
- NHS Loses Fight Over Publication of Antipsychotic Meds Brochures for Kids
- Genzyme's Termeer Got $50M in Compensation Over Last 3 Years; Wife Got Trips to Asia on Corporate Jet
- Merck Gives Snapshot of Combined Company: $47B in Sales; Just $7.6B in Cash
- Why Pfizer Wants Your Car-Sick Dog to Travel on Thanksgiving
- FDA Delays Genzyme's Lumizyme, Manufacturing Problems Blamed
- Will FDA Approve MannKind's Insulin Inhaler?
- VeriChip TV Ad Confirms Critics' Fears: They Want Everyone Implanted
- Hepatitis C Drugs Kill the Virus...and Your Sex Drive
- Microchip Implant to Link Your Health Records, Credit History, Social Security
- Biogen Idec's Social Media Ties Save Tysabri Again; FDA Watching
- NYT's MannKind Story Needlessly Quoted a Competitor Bashing Afresa
- Novartis CEO Sends Emails to 140 Animal Rights Activists:
- BioCryst's Antiviral Drug Peramivir Aims to Keep Swine-Flu Body Count Low
Subscribe to Pharma blog comments RSS 
- How NOT to Write a Biotech Press Release: Just Ask Epeius
- The 10 Weirdest Drug Stories of the Month
- Biogen Idec's Social Media Ties Save Tysabri Again; FDA Watching
- Teva, In Turnabout, Sues to Protect Its Multiple Sclerosis Drug Copaxone
- Fired Whistleblower Reps Make Similar Claim: Pfizer Said They Lacked "Integrity"
- BioCryst's Antiviral Drug Peramivir Aims to Keep Swine-Flu Body Count Low
- More Tysabri Problems; Time for a Biogen-Idec Credibility Check
- VeriChip TV Ad Confirms Critics' Fears: They Want Everyone Implanted
Industry Transcripts by Seeking Alpha
- How to choose the right insurance carrier for your business
- Real Estate: Prepare your properties to weather what lies ahead
- Technology: Be prepared if part of your global supply chain goes missing
Archives
Recommended Sources
About Pharma Industry
BNET Pharma provides daily industry trends and news coverage with insights for managers and executives about major manufacturers of pharmaceuticals and medicine. In addition to detailed drug company profiles, we bring you industry analysis on new partnerships, drug patents and products, cost management, investments, pharmaceutical related lawsuits, and a host of other important business issues.